Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

The partnership combines Ginkgo's AI/ML and enzyme engineering expertise with Prozomix's wealth of enzyme sequence data to create best-in-class enzymes for API manufacturing This agreement also marks ...

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.